Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
14
06
2021
accepted:
08
09
2021
pubmed:
30
10
2021
medline:
8
2
2022
entrez:
29
10
2021
Statut:
ppublish
Résumé
Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive primary peritoneal neoplasia. At diagnosis, few patients are eligible for a recommended cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Among neoadjuvant strategies, pressurized intraperitoneal aerosol chemotherapy (PIPAC) combined with systemic chemotherapy has been recently proposed. This study evaluated this strategy in a cohort of DMPM patients. Patients with DMPM and primary or recurrent non-resectable diseases who received at least one PIPAC procedure in alternation with systemic chemotherapy were included in this retrospective study to analyze oncologic outcomes. Overall, 26 DMPM patients were treated with at least one PIPAC, including 20 patients with no previous CRS. Of 22 patients (85%) who had symptoms, 9 had perceptible ascites. Overall, 79 PIPAC procedures were performed, with half of the patients receiving three PIPAC procedures or more. Among eight patients (31%), 10 adverse events (13% of procedures) were reported, including two severe complications, both corresponding to digestive perforations. Improvement of symptoms was reported for 32% of the patients, whereas control of ascites was noted in 46%. All but one procedure among 14 patients (54%) secondarily treated by CRS-HIPEC were considered complete resections. After a median follow-up period of 29.6 months (95% confidence interval [CI], 17.6-not reached [NR]), the median overall survival period was 12 months (95% CI 11.1-NR). The median progression-free survival (PFS) was significantly better among the patients who underwent resection than among those who did not (33.5 vs 7.4 months; hazard ratio [HR], 0.18; 95% CI 0.06-0.755; p < 0.001). For patients with initially non-resectable DMPM, PIPAC is feasible for treatment with neoadjuvant intent and could facilitate complete secondary resection.
Sections du résumé
BACKGROUND
BACKGROUND
Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive primary peritoneal neoplasia. At diagnosis, few patients are eligible for a recommended cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Among neoadjuvant strategies, pressurized intraperitoneal aerosol chemotherapy (PIPAC) combined with systemic chemotherapy has been recently proposed. This study evaluated this strategy in a cohort of DMPM patients.
METHODS
METHODS
Patients with DMPM and primary or recurrent non-resectable diseases who received at least one PIPAC procedure in alternation with systemic chemotherapy were included in this retrospective study to analyze oncologic outcomes.
RESULTS
RESULTS
Overall, 26 DMPM patients were treated with at least one PIPAC, including 20 patients with no previous CRS. Of 22 patients (85%) who had symptoms, 9 had perceptible ascites. Overall, 79 PIPAC procedures were performed, with half of the patients receiving three PIPAC procedures or more. Among eight patients (31%), 10 adverse events (13% of procedures) were reported, including two severe complications, both corresponding to digestive perforations. Improvement of symptoms was reported for 32% of the patients, whereas control of ascites was noted in 46%. All but one procedure among 14 patients (54%) secondarily treated by CRS-HIPEC were considered complete resections. After a median follow-up period of 29.6 months (95% confidence interval [CI], 17.6-not reached [NR]), the median overall survival period was 12 months (95% CI 11.1-NR). The median progression-free survival (PFS) was significantly better among the patients who underwent resection than among those who did not (33.5 vs 7.4 months; hazard ratio [HR], 0.18; 95% CI 0.06-0.755; p < 0.001).
CONCLUSIONS
CONCLUSIONS
For patients with initially non-resectable DMPM, PIPAC is feasible for treatment with neoadjuvant intent and could facilitate complete secondary resection.
Identifiants
pubmed: 34713369
doi: 10.1245/s10434-021-10983-2
pii: 10.1245/s10434-021-10983-2
doi:
Substances chimiques
Aerosols
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2104-2113Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005. Cancer Causes Control. 2009;20:935–44. https://doi.org/10.1007/s10552-009-9328-9 .
doi: 10.1007/s10552-009-9328-9
pubmed: 19294523
Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985–90. https://doi.org/10.1093/annonc/mdl345 .
doi: 10.1093/annonc/mdl345
pubmed: 17030547
Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827–34. https://doi.org/10.1093/annonc/mdl428 .
doi: 10.1093/annonc/mdl428
pubmed: 17130182
Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99:109–13. https://doi.org/10.1002/jso.21177 .
doi: 10.1002/jso.21177
pubmed: 19016259
Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42. https://doi.org/10.1200/JCO.2009.23.9640 .
doi: 10.1200/JCO.2009.23.9640
pubmed: 19917862
Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2014;22:1686–93. https://doi.org/10.1245/s10434-014-3978-x .
doi: 10.1245/s10434-014-3978-x
pubmed: 25124472
Miura JT, Johnston FM, Gamblin TC, Turaga KK. Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol. 2014;21:3947–53. https://doi.org/10.1245/s10434-014-3803-6 .
doi: 10.1245/s10434-014-3803-6
pubmed: 24841356
Bijelic L, Darcy K, Stodghill J, Tian C, Cannon T. Predictors and outcomes of surgery in peritoneal mesothelioma: an analysis of 2000 patients from the National Cancer Database. Ann Surg Oncol. 2020;39:576–9. https://doi.org/10.1245/s10434-019-08138-5 .
doi: 10.1245/s10434-019-08138-5
Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2020;47:36–59. https://doi.org/10.1016/j.ejso.2020.02.011 .
doi: 10.1016/j.ejso.2020.02.011
pubmed: 32209311
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: management of peritoneal mesothelioma. Ann Surg Oncol. 2020;19:1–6. https://doi.org/10.1245/s10434-020-08324-w .
doi: 10.1245/s10434-020-08324-w
Le Roy F, Gelli M, Hollebecque A, et al. Conversion to complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma after bidirectional chemotherapy. Ann Surg Oncol. 2017;24:3640–6. https://doi.org/10.1245/s10434-017-6033-x .
doi: 10.1245/s10434-017-6033-x
pubmed: 28849389
Sgarbura O, Gourgou S, Tosi D, et al. MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma. Pleura Peritoneum. 2019;4:20190010. https://doi.org/10.1515/pp-2019-0010 .
doi: 10.1515/pp-2019-0010
pubmed: 31417958
pmcid: 6693480
Ali YM, Sweeney J, Shen P, et al. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on quality of life in patients with peritoneal mesothelioma. Ann Surg Oncol. 2020;27:117–23. https://doi.org/10.1245/s10434-019-07425-5 .
doi: 10.1245/s10434-019-07425-5
pubmed: 31069554
Fujimoto E, Kijima T, Kuribayashi K, et al. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. Expert Rev Anticancer Ther. 2017;17:865–72. https://doi.org/10.1080/14737140.2017.1340157 .
doi: 10.1080/14737140.2017.1340157
pubmed: 28594258
Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49:3140–8. https://doi.org/10.1016/j.ejca.2013.05.027 .
doi: 10.1016/j.ejca.2013.05.027
pubmed: 23831335
Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. Eur J Cancer. 2016;65:69–79. https://doi.org/10.1016/j.ejca.2016.06.002 .
doi: 10.1016/j.ejca.2016.06.002
pubmed: 27472649
Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43:1228–35. https://doi.org/10.1016/j.ejso.2017.01.009 .
doi: 10.1016/j.ejso.2017.01.009
pubmed: 28189456
Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547–50.
doi: 10.1007/BF01225271
Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1–11.
pubmed: 626987
Bartlett DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer. 1998;83:1251–61.
doi: 10.1002/(SICI)1097-0142(19980915)83:6<1251::AID-CNCR27>3.0.CO;2-3
Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000;87:1587–93. https://doi.org/10.1046/j.1365-2168.2000.01571.x .
doi: 10.1046/j.1365-2168.2000.01571.x
pubmed: 11091251
Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol. 2003;83:147–53. https://doi.org/10.1002/jso.10255 .
doi: 10.1002/jso.10255
pubmed: 12827682
Kluger MD, Taub RN, Hesdorffer M, Jin Z, Chabot JA. Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: operative MORBIDITY and mortality in phase I and II trials. Eur J Surg Oncol. 2010;36:997–1003. https://doi.org/10.1016/j.ejso.2010.07.001 .
doi: 10.1016/j.ejso.2010.07.001
pubmed: 20674253
Leinwand JC, Taub RN, Chabot JA, Kluger MD. Two-stage cytoreductive surgery and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: predictors of overall survival in an intention-to-treat series. Ann Surg Oncol. 2019;33:2539–47. https://doi.org/10.1245/s10434-019-08139-4 .
doi: 10.1245/s10434-019-08139-4
Solass W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26:1849–55. https://doi.org/10.1007/s00464-012-2148-0 .
doi: 10.1007/s00464-012-2148-0
pubmed: 22580869
Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20:e368–77. https://doi.org/10.1016/S1470-2045(19)30318-3 .
doi: 10.1016/S1470-2045(19)30318-3
pubmed: 31267971
Davigo A, Passot G, Vassal O, et al. PIPAC versus HIPEC: cisplatin spatial distribution and diffusion in a swine model. Int J Hyperthermia. 2020;37:144–50. https://doi.org/10.1080/02656736.2019.1704891 .
doi: 10.1080/02656736.2019.1704891
pubmed: 32003300
Girshally R, Demtröder C, Albayrak N, Zieren J, Tempfer C, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2016;14:253. https://doi.org/10.1186/s12957-016-1008-0 .
doi: 10.1186/s12957-016-1008-0
pubmed: 27678344
pmcid: 5039790
Giger-Pabst U, Demtröder C, Falkenstein TA, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer. 2018;18:442. https://doi.org/10.1186/s12885-018-4363-0 .
doi: 10.1186/s12885-018-4363-0
pubmed: 29669524
pmcid: 5907219
Alyami M, Mercier F, Siebert M, et al. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2019;47:128–33. https://doi.org/10.1016/j.ejso.2019.06.028 .
doi: 10.1016/j.ejso.2019.06.028
pubmed: 31253545
Agha R, Abdall-Razak A, Crossley E, et al. STROCSS 2019 guideline: strengthening the reporting of cohort studies in surgery. Int J Surg. 2019;72:156–65. https://doi.org/10.1016/j.ijsu.2019.11.002 .
doi: 10.1016/j.ijsu.2019.11.002
pubmed: 31704426
Siebert M, Alyami M, Mercier F, et al. Severe hypersensitivity reactions to platinum compounds post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report. Cancer Chemother Pharmacol. 2019;83:425–30. https://doi.org/10.1007/s00280-018-3740-3 .
doi: 10.1007/s00280-018-3740-3
pubmed: 30511218
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.
doi: 10.1007/978-1-4613-1247-5_23
Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol. 2018;150:23–30. https://doi.org/10.1016/j.ygyno.2018.05.001 .
doi: 10.1016/j.ygyno.2018.05.001
pubmed: 29743140
Solass W, Sempoux C, Carr NJ, et al. Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis. Histopathology. 2019;74:1014–24. https://doi.org/10.1111/his.13829 .
doi: 10.1111/his.13829
pubmed: 30687944
Benzerdjeb N, Durieux E, Tantot J, et al. Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis. Histopathology. 2020;77:548–59. https://doi.org/10.1111/his.14092 .
doi: 10.1111/his.14092
pubmed: 32060943
Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.
doi: 10.1097/00000658-199501000-00004
Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980;68:356–62.
doi: 10.1016/0002-9343(80)90103-5
Lainakis G, Zagouri F, Kastritis E, et al. Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single-institution experience. Tumori J. 2011;97:25–9.
doi: 10.1177/030089161109700105
Alyami M, Bonnot P-E, Mercier F, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol. 2021;47:123–27. https://doi.org/10.1016/j.ejso.2020.05.021 .
doi: 10.1016/j.ejso.2020.05.021
Tavernier C, Passot G, Vassal O, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) might increase the risk of anastomotic leakage compared to HIPEC: an experimental study. Surg Endosc. 2019;17:2939–46. https://doi.org/10.1007/s00464-019-07076-3 .
doi: 10.1007/s00464-019-07076-3
Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1093–100. https://doi.org/10.1245/s10434-012-2845-x .
doi: 10.1245/s10434-012-2845-x
pubmed: 23456386